A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Clinical trial NCT05552222 · RECRUITING

Trial details

NCT number: NCT05552222
Sponsor: Janssen Research & Development, LLC
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Multiple Myeloma

Start date: 2022-10-25
Primary completion: 2031-04-30
Enrollment: 1590

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.